A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension
Open Access
- 1 April 2021
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 11 (2) , 1-9
Abstract
Several patient‐reported outcome measures have been developed to assess health status in pulmonary arterial hypertension. The required change in instrument scores needed, to be seen as meaningful to the individual, however remain unknown. We sought to identify minimal clinically important differences in the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and to validate these against objective markers of functional capacity. Minimal clinically important differences were established from a discovery cohort (n = 129) of consecutive incident cases of idiopathic pulmonary arterial hypertension with CAMPHOR scores recorded at treatment‐naïve baseline and 4–12 months following pulmonary arterial hypertension therapy. An independent validation cohort (n = 87) was used to verify minimal clinically important differences. Concurrent measures of functional capacity relative to CAMPHOR scores were collected. Minimal clinically important differences were derived using anchor‐ and distributional‐based approaches. In the discovery cohort, mean (SD) was 54.4 (16.4) years and 64% were female. Most patients (63%) were treated with sequential pulmonary arterial hypertension therapy. Baseline CAMPHOR scores were: Symptoms, 12 (7); Activity, 12 (7) and quality of life, 10 (7). Pulmonary arterial hypertension treatment resulted in significant improvements in CAMPHOR scores (p < 0.05). CAMPHOR minimal clinically important differences averaged across methods for health status improvement were: Symptoms, –4 points; Activity, –4 points and quality of life –3 points. CAMPHOR Activity score change ≥minimal clinically important difference was associated with significantly greater improvement in six‐minute walk distance, in both discovery and validation populations. In conclusion, CAMPHOR scores are responsive to pulmonary arterial hypertension treatment. Minimal clinically important differences in pulmonary hypertension‐specific scales may provide useful insights into treatment response in future clinical trials.Keywords
Funding Information
- National Institute for Health Research
This publication has 43 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertensionBMC Pulmonary Medicine, 2013
- Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patientsHealth and Quality of Life Outcomes, 2013
- The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)Health and Quality of Life Outcomes, 2012
- United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)The Journal of Heart and Lung Transplantation, 2008
- Minimal Clinically Important Change for Pain Intensity, Functional Status, and General Health Status in Patients With Nonspecific Low Back PainSpine, 2006
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- Determining Clinically Important Differences in Health Status MeasuresPharmacoEconomics, 1999
- Measurement of health statusControlled Clinical Trials, 1989
- Effect Sizes for Interpreting Changes in Health StatusMedical Care, 1989